Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Ophthalmol. 2014 Jun 24;8:1187-98. doi: 10.2147/OPTH.S40350. eCollection 2014.

Ranibizumab for the treatment of degenerative ocular conditions.

Author information

  • 1Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece.
  • 2Department of Ophthalmology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Switzerland.
  • 3Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece ; Beyoglou Eye Research and Teaching Hospital, Istanbul University, Istanbul, Turkey.
  • 4Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece ; Department of Ophthalmology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Switzerland.

Abstract

Degenerative ocular conditions, such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and myopic degeneration, have become a major public health problem and a leading cause of blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs seem to be an effective and safe treatment for these conditions. Ranibizumab, a humanized monoclonal antibody antigen-binding fragment, which inhibits all biologically active isoforms of VEGF-A, is still the gold standard treatment for the majority of these pathological entities. In this review, we present the results of the most important clinical trials concerning the efficacy and safety of ranibizumab for the treatment of degenerative ocular conditions.

KEYWORDS:

age-related macular degeneration; anti-VEGF; diabetic macular edema; efficacy; quality of life; retinal vein occlusion; safety

PMID:
25028531
[PubMed]
PMCID:
PMC4077856
Free PMC Article

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk